Stellar Biotechnologies, Inc. (NASDAQ:SBOT) was founded in 2007 and is headquartered in Port Hueneme, California, USA. It has 25 full-time employees. It is a pharmaceutical and agricultural biotechnology company engaged in keyhole limpets in Europe, North America and Asia. Keyhole Limpet Hemocyanin (KLH) aquaculture, research, development, production and commercialization.
Stellar Biotechnologies (SBOT):
Stellar Biotechnologies focuses on Keyhole Limpet Hemocyanin (KLH) protein, and the company focuses on the rapidly developing field of immunotherapy.
KLH is an important immunostimulatory molecule, widely used as an active pharmaceutical ingredient (API) in many new immunotherapies, and as an injectable product for evaluating immune response. This multifunctional molecule has a long history of safe and effective use in a wide range of disease indications (cancer, inflammatory diseases, Alzheimer’s disease and immune diseases) and research applications.
Stellar Biotechnology is KLH’s leader in sustainable production. It still applied decades of professional aquaculture science to the pharmaceutical industry and created the only KLH production facility of its kind. Stellar has developed a proprietary capability to sustainably produce GMP-grade KLH and set an unprecedented benchmark for its manufacturing and sustainable supply.
Stellar’s customers and partners include multinational pharmaceutical companies, well-known research centers, and developers of active immunotherapy and therapeutic vaccines. The complexity and versatility of KLH molecules and the growing demand for commercial-scale GMP-grade KLH provide many business opportunities for Stellar.
Stellar’s core business is the production and supply of KLH protein under the Stellar KLH™ brand. The products include Stellar KLH™ proteins in various grades, formulations and configurations for clinical and research applications. Stellar KLH™ can be used for therapeutic vaccine conjugation, as a carrier molecule in immunotherapy, and as an immunostimulant in immunotoxicology applications.
Stellar Biotechnologies, Inc. is committed to applying the company’s Stellar KLH™ platform to power the growing field of disease-targeted immunotherapy.